Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is ...
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
Discover how outsourcing regulatory submission content development improves efficiency and ensures compliance.
The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...
Andhra Pradesh SIPB approves ₹3.10 lakh crore investments, targeting 3.12 lakh jobs, including major projects by ...
Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton ...
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development ...
If approved, clesrovimab will directly compete ... The FDA has accepted a New Drug Application (NDA) for sebetralstat for the on-demand treatment of HAE attacks in adult and paediatric patients ...
Zacks Investment Research on MSN1d
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback